A PE/VC firm based in China makes early-growth stage investments in several sectors including Healthcare. The firm typically invests USD 5-10 million per company. The firm typically invests in companies located in China but is also interested in companies abroad that have a China angle. For example, companies that plan to set up a JV in China, etc. The firm has no set number of investments it plans to make but could potentially invest in 3-4 healthcare companies in the next 12 months. The firm is actively seeking new investment opportunities.
In Healthcare, the firm seeks to invest in therapeutics, diagnostics, medical equipment/devices, services, and HCIT. The firm is generally opportunistic in terms of subsectors. However, the firm is particularly interested in implantable devices, biomesh, IVD, gene sequencing, and vaccines. For indications, the firm is interested in large markets in China; stated interest includes (but not limited to) orthopedics, oncology, diabetes and obesity, viral diseases, and hepatitis B & C. In terms of stage of development, the firm will consider early-late stages for Chinese companies. For foreign companies, the firm seeks products that already have regulatory approval in their respective market. However, the firm is open to engage with companies with products that are 1-2 years from market approval.
The firm invests in companies in China as well as companies located abroad. However, companies abroad must have a China angle. For example, plans to set up a JV. The firm generally seeks board of directors representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: China PE/VC Firm Invests Up to $10M in Life Science Companies With China Market Potential
15 OctHot Investor Mandate: New VC Firm Interested in USA Investment Opportunities in Biotech, Digital Health, Medtech, and More
15 OctA newly established venture capital firm is actively seeking early-stage investment opportunities in life sciences and healthcare sectors. The firm is focused on emerging companies in pre-seed / seed rounds and will participate in Series A at the maximum. Currently, the firm is focused on USA-based companies, but can dedicate up to 20% of their fund to invest outside of the USA.
The firm invests in 4 main focus areas: (1) biotech, which includes biomarkers, liquid biopsies, cell therapy, smart packaging, drug delivery, next generation sequencing, omics; (2) digital health, which includes wearables, diagnostics, services, AI-enabled approaches, management, fitness, digital therapy; (3) medtech, which includes smart devices, smart lens, breath biopsy, 3D printing, in vitro diagnostics, surgical robotics, laser therapy; (4) health edtech, which includes personalized learning, med. professional development, immersive learnings (e.g., VR), wellness. The firm plans to expand their investment capabilities in medtech, as they have recently made great investments in this space. The firm is indication agnostic, and is open to all opportunities including oncology, cardiovascular, infectious, metabolic, neurological, and rare/orphan diseases.
The firm seeks to work with companies backed by a management team with deep domain expertise and technologies that are backed by solid IP. The firm prefers to act as a follow-on, but will seek to lead more investment rounds in the future.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Canadian Investment Firm Seeks Opportunities in Therapeutics, Medtech, Diagnostics Sectors Across North America
15 OctA venture capital firm based in Canada is making seed and venture investments with its latest fund, and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm prefers to lead financing rounds of Canadian companies and co-lead investments based in the United States.
The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway.
The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Europe VC With Over $1B AUM Invests in Medtech, Digital Health, Life Science Tools Across All Stages of Development
15 OctA firm with multiple offices in Western Europe has over €1 billion in total assets under management. The firm typically invests €1-5 million in early-stage opportunities or up to €10 million in growth-stage opportunities. The firm is currently focused on companies based in Europe.
Within the life science sector, the firm is currently focused on medical technology, diagnostics, life science tools and platforms, and digital health across Europe. The firm is open to opportunities in any indication area and at any phase of development.
The firm is open to investing in companies at early stages with a proof-of-concept, clinically relevant data and/or strong IP positions.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Make Your First Move to the Chinese Market
8 Oct
 Baylor Wei |
An Interview with Baylor Wei, CEO, Yuhang Capital By Candice He, Global Investment Strategist, LSN |
Candice He (CH): Hi Baylor, could you briefly introduce Yuhang Capital and its mandate of the early-stage life science investments?
Baylor Wei (BW): Yuhang Capital aims to cultivate innovation, support entrepreneurs, and ultimately realize the vision of improving human health and creating better life. We are headquartered in San Francisco, California, and have office in Hangzhou, China. Our team manages both an USD and an RMB fund across public and private company investments worldwide.
We provide seed funding to help start-ups go from 0 to 1. At this stage, we are mainly looking for a driven team who are working to solve a pressing problem, who can really innovate, and who have a clear plan to eliminate their technology risks at the lowest possible cost. We are dedicated to creating long-term value for our portfolios and the larger start-up community.
CH: As you’ve mentioned, Yuhang has offices in both China and the U.S. Compared to other countries, do you think the Chinese market is especially suitable for life science start-ups to grow?
BW: Absolutely. China has expanded to be the second largest pharmaceutical market globally with $137 billion USD in total spending in 2018. Over the past 5 years, China has gradually become the strategic hub for multi-national pharmaceutical companies. For example, Pfizer has moved three of its research units to China to bring more developed products to the country; in 2019, Sanofi also launched new business unit “China and Emerging Markets” to leverage the tremendous growth opportunities in these markets. The Chinese market has made up 4%-18% of the global revenue for multi-national pharmaceutical companies, which also shows its great potential.
In addition, the policy in China has shifted to support more the use of IoT and other innovative technologies to solve healthcare problems. This is also what we are most interested in. As an example, we have been working with the CITRIS and the Banatao Institute to build CITRIS-Zhejiang, with the focus on the intersection of technology and healthcare. Finally, while the healthcare resources in China had been increasing in recent years, there is still a big gap given the large population. In the coming ten years, we expect even higher demands for talents, technology and innovative drugs and medical devices to fill in the gaps in the Chinese healthcare industry.
CH: Could you specify what kind of company Yuhang is looking for in this competition, in terms of sectors, indications, or stage of development? Does Yuhang have a geographic preference?
BW: We are interested in start-ups who use innovative technology to address key issues in life science and healthcare. These include, but are not limited to biopharmaceuticals, medical devices, diagnostics, human therapeutics, digital medicine and health services. We believe innovation should have no borders. We welcome teams from any geographical area to join in this global movement. We try to impose less restriction on eligibility for the competition, but we are looking for great science and a driven team.
CH: That sounds like a great fit for the LSN start-up community! How many winners will be selected? Will they receive cash rewards or service supports?
BW: In total, 16 winners will be selected and will be getting both cash rewards and service supports. The First Prize will receive 6 million RMB, up to 10 million RMB interest-free bank loan and up to three-year free office space of 1,000 square meters. In addition, Yuhang Capital and our partnering venture capital funds will also consider follow-on investment based on further due diligence.
CH: Can’t say no to that! So how did Yuhang get involved in hosting this competition? What is Yuhang’s long-term vision? Would you focus on equity investments or are you ready to do more on top of the investment?
BW: The reasons that Yuhang decided to host this competition is exactly due to our long-term vision, which is to cultivate innovation, support entrepreneurs, and ultimately realize the vision of improving human health and creating better life. We are committed to bringing long-term value to the global healthcare community, and this has to be coming from equity investments and beyond.
CH: Thank you very much for the interview, Baylor.
For our readers who want to know more about Yuhang Capital, please visit Yuhang’s Sponsor Dedicated Webpage.
Apply to 2020 Global Biotechnology Innovation and Entrepreneurship Competition Before Oct.18th Here.
Healthtech Partnering Week: Call for Panelists!
8 OctBy Rory McCann, Marketing Manager & Conference Producer, LSN
The Inaugural Life Science Nation (LSN) Healthtech Partnering Week 2021 launches January 11-15, 2021 with three back-to-back digital partnering conferences: Redefining Early Stage Investments (RESI), 4D Meets AI, and Longevity, Health & Innovation (LHI). These three events make up the ultimate partnering experience within healthcare and life science through their match-based partnering system, as well as pitch sessions, informational workshops, and panels.
Panels have been a valuable resource for both early-stage companies and investors to learn how other industry professionals are navigating challenges and building successful businesses and partnerships. Participants increase their exposure in addition to receiving complimentary registration in return for adding such value to attendees. We are still accepting applications for new panelists, and if you are an early-stage company developing new tech to advance healthcare or an investor with industry insight, joining a panel gives you increased exposure to share your story with our community. Read more about the events and apply to join a panel!
Redefining Early-Stage Investments (RESI) – January 11-13, 2021
The Redefining Early Stage Investments (RESI) conference series was created by Life Science Nation (LSN) to bring together startups with early-stage investors and strategic channel partners to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. RESI is cross-border and cross-domain, connecting start-ups with ten categories of global investors across the silos of drugs, devices, diagnostics, and digital health. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding.
Apply to be on a RESI Panel (Investors Only)!
4D Meets AI (4D) – January 14-15, 2021
Artificial intelligence (AI) is rapidly reshaping the healthcare landscape, and redefining what is possible in life science. The business of AI is broken down into two groups: the buyers and the sellers. 4D Meets AI is a partnering conference that connects the investors and strategic partners and matches them to companies developing and commercializing AI technology in drugs, devices, diagnostics, and digital health (the 4 Ds) to revolutionize healthcare. In addition to pitch sessions and one-on-one meetings hosted by our premier partnering platform, 4D Meets AI features investor and application panels to expand your knowledge of the industry and learn the latest trends and developments. This two-day digital conference provides the opportunity to meet strategic partners, learn from the experts, and build relationships to advance the future of healthcare.
Apply to be on a 4D Panel (Investors and CEOs)!
Longevity, Health & Innovation (LHI), Co-Organized with Mary Furlong & Associates – January 14-15, 2021
The aging boomer population contributed $8.3 trillion in economic activity to the 2018 US economy, and that number is projected to triple by 2050. The need for advancements in drugs, devices, diagnostics, and digital health for the treatment of age-related conditions is crucial. Longevity, Health & Innovation (LHI) is a new partnering conference focused on conditions related to aging, market challenges, and solutions via early-stage companies and their promising tech and products. LHI brings fundraising startups together with investors in longevity innovation to make deals in order that today’s seniors live longer, healthier lives.
Apply to be on an LHI Panel (Investors Only!)
See Who Will Be at Digital RESI November
8 OctBy Jessica Yang, Senior Research Analyst, Asia Business Development, LSN
The next Digital Redefining Early Stage Investments (RESI) conference is coming soon November 17-19, 2020. Whether identifying a lead investor, filling out a funding round, or exploring strategic partnerships, Digital RESI has a robust pool of groups to network with. Digital RESI provides a unique partnering platform with full video integration through which attendees can determine a potential fit and make valuable connections between companies and investors. LSN has been overwhelmed by the investor interest in this event, with almost 150 investors signed up in only the first two weeks.
We expect a total of over 300 investors at the upcoming Digital RESI. Take a look at those who are already committed and register here to meet them digitally!
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 